Tyme Technologies, Inc. (NASDAQ:TYME) COO Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $3.34, for a total value of $167,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Tyme Technologies, Inc. (TYME) traded up $0.27 during trading hours on Friday, reaching $4.00. The company’s stock had a trading volume of 559,051 shares, compared to its average volume of 109,972. Tyme Technologies, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $9.50.

ILLEGAL ACTIVITY NOTICE: “Michael Demurjian Sells 50,000 Shares of Tyme Technologies, Inc. (TYME) Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/18/michael-demurjian-sells-50000-shares-of-tyme-technologies-inc-tyme-stock.html.

Separately, Evercore ISI initiated coverage on Tyme Technologies in a research note on Friday. They set an “outperform” rating and a $7.00 price objective on the stock.

About Tyme Technologies

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Receive News & Stock Ratings for Tyme Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies Inc. and related stocks with our FREE daily email newsletter.